Please use this identifier to cite or link to this item:
|Title:||Analysis of a Novel pncA Mutation for Susceptibility to Pyrazinamide Therapy.|
|Authors:||Karmakar, Malancha;Globan, Maria;Fyfe, Janet A M;Stinear, Timothy P;Johnson, Paul D R;Holmes, Natasha E;Denholm, Justin T;Ascher, David B|
|Affiliation:||University of Melbourne Bio21 Molecular Science and Biotechnology Institute, Department of Biochemistry and Molecular Biology, Parkville, Victoria, Australia|
University of Melbourne, Victorian Tuberculosis Program, Melbourne Health, Melbourne, Victoria, Australia
Doherty Institute for Infection and Immunity, Department of Microbiology and Immunology , Melbourne, Victoria, Australia
Victorian Infectious Diseases Reference Laboratory (VIDRL), Mycobacterium Reference Laboratory, Melbourne, Victoria, Australia
World Health Organization Collaborating Centre for Mycobacterium ulcerans, Melbourne, Victoria, Australia
Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia
Victorian Infectious Diseases Service and Department of Microbiology and Immunology, at the Peter Doherty Institute for Infection and Immunity,, Parkville, Australia
University of Cambridge, Department of Biochemistry, Cambridge, Cambridgeshire, United Kingdom of Great Britain and Northern Ireland
|Citation:||American journal of respiratory and critical care medicine 2018; online first: 25 April|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.